	US 11,980,611 B2
	Treating sickle cell disease with a pyruvate kinase R activating compound
Anna Ericsson, Shrewsbury, MA (US); Neal Green, Newton, MA (US); Gary Gustafson, Ridgefield, CT (US); Bingsong Han, Westwood, MA (US); David R. Lancia, Jr., Boston, MA (US); Lorna Mitchell, Cambridge (NZ); David Richard, Littleton, MA (US); Tatiana Shelekhin, Watertown, MA (US); Chase C. Smith, Watertown, MA (US); Zhongguo Wang, Lexington, MA (US); and Xiaozhang Zheng, Watertown, MA (US)
Assigned to Novo Nordisk Health Care AG, Zurich (CH)
Filed by Novo Nordisk Health Care AG, Zurich (CH)
Filed on Dec. 22, 2022, as Appl. No. 18/087,774.
Application 18/087,774 is a continuation of application No. 17/008,787, filed on Sep. 1, 2020, abandoned.
Application 17/008,787 is a continuation of application No. 16/576,720, filed on Sep. 19, 2019, abandoned.
Claims priority of provisional application 62/811,904, filed on Feb. 28, 2019.
Claims priority of provisional application 62/789,641, filed on Jan. 8, 2019.
Claims priority of provisional application 62/782,933, filed on Dec. 20, 2018.
Claims priority of provisional application 62/733,558, filed on Sep. 19, 2018.
Claims priority of provisional application 62/733,562, filed on Sep. 19, 2018.
Prior Publication US 2023/0381151 A1, Nov. 30, 2023
Int. Cl. A61K 31/436 (2006.01); A61K 9/00 (2006.01); A61P 7/06 (2006.01); C07D 487/04 (2006.01); C07D 491/056 (2006.01)

CPC A61K 31/436 (2013.01) [A61K 9/0053 (2013.01); A61P 7/06 (2018.01); C07D 487/04 (2013.01); C07D 491/056 (2013.01)]

4 Claims

1. A compound 1-(5-((4-(difluoromethoxy)phenyl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2,2-dimethylpropan-1-one, or a pharmaceutically acceptable salt thereof.